- Home
- KAVL vs GLMD Comparison
KAVL vs GLMD Comparison
Compare KAVL & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAVL
- GLMD
- Stock Information
- Founded
- KAVL 1998
- GLMD 2000
- Country
- KAVL United States
- GLMD Israel
- Employees
- KAVL N/A
- GLMD N/A
- Industry
- KAVL Medicinal Chemicals and Botanical Products
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- KAVL Health Care
- GLMD Health Care
- Exchange
- KAVL Nasdaq
- GLMD Nasdaq
- Market Cap
- KAVL 9.6M
- GLMD 8.0M
- IPO Year
- KAVL N/A
- GLMD 2014
- Fundamental
- Price
- KAVL $0.60
- GLMD $1.37
- Analyst Decision
- KAVL
- GLMD Hold
- Analyst Count
- KAVL 0
- GLMD 1
- Target Price
- KAVL N/A
- GLMD N/A
- AVG Volume (30 Days)
- KAVL 5.3M
- GLMD 72.8K
- Earning Date
- KAVL 09-16-2025
- GLMD 11-13-2025
- Dividend Yield
- KAVL N/A
- GLMD N/A
- EPS Growth
- KAVL N/A
- GLMD N/A
- EPS
- KAVL N/A
- GLMD N/A
- Revenue
- KAVL $1,127,037.00
- GLMD N/A
- Revenue This Year
- KAVL N/A
- GLMD N/A
- Revenue Next Year
- KAVL N/A
- GLMD N/A
- P/E Ratio
- KAVL N/A
- GLMD N/A
- Revenue Growth
- KAVL N/A
- GLMD N/A
- 52 Week Low
- KAVL $0.40
- GLMD $1.15
- 52 Week High
- KAVL $1.55
- GLMD $4.81
- Technical
- Relative Strength Index (RSI)
- KAVL 50.36
- GLMD 40.59
- Support Level
- KAVL $0.57
- GLMD $1.37
- Resistance Level
- KAVL $0.65
- GLMD $1.50
- Average True Range (ATR)
- KAVL 0.07
- GLMD 0.10
- MACD
- KAVL 0.02
- GLMD -0.02
- Stochastic Oscillator
- KAVL 79.64
- GLMD 6.67
About KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating creative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.